3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
18
Neoplasms
11
Venous Thrombosis
9
Pulmonary Embolism
9
Thrombosis
5
Multiple Myeloma
4
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Carboplatin
71
Docetaxel
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled